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I am delighted to welcome you to Infectious
Diseases and Therapy. Launched in January
2012, the journal focuses on the exciting but
challenging times within the infectious diseases
therapeutic area. The international, peer-
reviewed journal publishes concise and high-
quality papers in all areas of infectious diseases,
including but not limited to, microbiology,
epidemiology, virology, sexually transmitted
diseases, pandemics and epidemics, new and
emerging infections, chronic infections,
vaccines, drug-resistant pathogens, tropical
diseases, and all other infection-related
problems that clinicians and researchers face
on a daily basis.
The journal publishes all types of research,
from preclinical through to post-marketing
and observational studies, diagnostic,
pharmacoeconomic, public health, educational,
and quality of life studies as well as case reports,
concise reviews and brief reports. It can also
publish supplements and special issues, either
based around a collection of articles on the same
topic, or on sponsored meeting proceedings,
roundtable discussions, case series, or similar.
Infectious Diseases and Therapy is an
open access journal, allowing widespread
dissemination of information, which is
additionally enhanced by a number of features
that appear online alongside the papers. All
articles also have a freely accessible bulleted
summary slide, displaying the key points of the
paper, to encourage readership to a broader
audience and enhance the educational value of
the paper. Other optional enhanced features
include slide decks, animations, videos and
interactive quizzes, all of which are peer
reviewed and open access. To meet the
ever-growing demand to publish research
quickly, Infectious Diseases and Therapy is a
rapid publication journal, with a peer review
decision reached within 2 weeks from
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submission, and acceptance to online
publication within 3–4 weeks.
The journal’s primary focus is to provide up-
to-date, high-quality and relevant information
by the most effective and educational methods
for infectious diseases clinicians, researchers
and the pharmaceutical industry. I look
forward to driving the success of this journal
forwards and believe that the journal will be a
welcome and valued addition to the world of
infectious diseases.
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